NeuroSense Therapeutics Ltd. (NRSN)
NRSNNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.74
-0.2450 (-12.37%) today
Regular session, Nov 11, 1:15 PM ET
- Market cap
- $3.29m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.73 to $2.08
- 52-week range
- $1.10 to $25.40
- Average volume
- 33.5k
- Previous close
- $1.98
Analysts
3 coveringHold1 buy, 2 hold, 0 sell
Targets a year out average $3.50, +101.7% from here
Earnings
Next report
Financials
No quarterly figures from the source.
News
8 latest- NeuroSense Therapeutics Consensus Price Target Increased by 15.35% to $113.39Fintel · 1 day ago
- NeuroSense Therapeutics Ltd. Targets Revenues in 2027 Under Strategic Collaboration AgreementFintel · Oct 26, 2026
- NeuroSense Targets Traumatic Brain Injury With New PrimeC Patent Application RTTNews · Oct 19, 2026
- NeuroSense Appeals Nasdaq Delisting Determination, Hearing Date Set For Nov. 10 RTTNews · Oct 14, 2026
- NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71Fintel · Oct 2, 2026
- NeuroSense H1 Net Loss Narrows; Targets December NDS Filing For PrimeC In ALS RTTNews · Sep 28, 2026
- HC Wainwright & Co. initiates coverage of NeuroSense Therapeutics (NRSN) with a Buy ratingFintel · Sep 4, 2026
- NeuroSense Unveils Accelerated, Capital-Efficient PrimeC Development Strategy In ALS RTTNews · Sep 3, 2026
The company
NeuroSense Therapeutics is a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- neurosense-tx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.